Hopace 5 Tablet contains Ramipril 5 mg, an angiotensin-converting enzyme (ACE) inhibitor primarily indicated for the management of hypertension, congestive heart failure, and for reducing the risk of cardiovascular events in high-risk patients. Ramipril works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation, reducing peripheral vascular resistance, and decreasing blood pressure. This mechanism also reduces the workload on the heart and improves cardiac output. Hopace 5 is effective in preventing stroke, myocardial infarction, and cardiovascular mortality in patients with established vascular disease or diabetes with end-organ damage. The tablet is typically administered once daily, with or without food, and dosage adjustments may be necessary based on renal function and clinical response. Common side effects include cough, dizziness, hypotension, and elevated serum potassium levels. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy, pregnancy, and bilateral renal artery stenosis. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment. Hopace 5 should be used under medical supervision to ensure optimal therapeutic outcomes and minimize adverse effects.